Randomized phase 2a study of TAS5315, a Bruton's tyrosine kinase inhibitor, for chronic spontaneous urticaria.

Authors

Michihiro Hide, Atsushi Fukunaga, Koremasa Hayama, Naoko Inomata, Shunsuke Takahagi, Tokuya Omi, Masaru Igarashi, Ryuji Maruyama, Akiko Yagami

Published in

Allergology international : official journal of the Japanese Society of Allergology. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

Chronic spontaneous urticaria (CSU) is a chronic skin disorder primarily driven by mast cell activation and basophil involvement. CSU is often associated with autoimmune mechanisms, positioning Bruton's tyrosine kinase (BTK) inhibition as an attractive therapeutic strategy. TAS5315 is a once-daily oral inhibitor of BTK with activity against Tec tyrosine-protein kinase and IL-2-inducible T-cell kinase (ITK). This study evaluated the efficacy and safety of TAS5315 in patients with CSU inadequately responding to non-sedating second-generation H1 receptor antagonists (ns-antihistamines).
This Phase 2a, randomized, double-blind, parallel-group, multicenter study randomized patients (1:1:1:1:1:1) with CSU to TAS5315 4 mg, 2 mg, 1 mg, 0.5 mg, 0.25 mg, or placebo for 12 weeks. The primary endpoint was the change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 12.
Of 126 patients enrolled, all received study treatment (n = 21 per dose group). The primary endpoint, mean changes from baseline in UAS7 at Week 12 were -17.15, -16.01, -15.19, -11.63, -17.84, and -9.06 for the TAS5315 4 mg, 2 mg, 1 mg, 0.5 mg, 0.25 mg, and placebo groups, respectively. Similar improvements were observed with TAS5315 versus placebo for other efficacy endpoints. Adverse events (AEs) were reported in over half of patients in each treatment group, and most were mild in severity. The most frequently reported AE with TAS5315 was petechiae.
Once-daily TAS5315 was well tolerated and showed promising efficacy, making it a potential treatment option for CSU patients with inadequate response to ns-antihistamines.

PMID:
42448553
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.